GlassScriptPhysician profile
Whitney B Frame
NPI 1336798792
$2,530.53
in general payments reported to CMS, 2019-2025
35 companies · $575 in 2025
The $575 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $362 · 2022: $368 · 2023: $552 · 2024: $674 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,800.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $323.72 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $308.55 | 2023-2025 | |
| Lilly USA, LLC | $296.73 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Biotech, INC. | $148.88 | 2021-2022 | |
| Lundbeck LLC | $134.69 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $114.33 | 2021-2025 | Eliquis, Opdivo |
| Otsuka America Pharmaceutical, INC. | $107.95 | 2023-2025 | Rexulti |
| Seagen INC. | $107.04 | 2021 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2021 | |
| Exact Sciences Corporation | $98.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Neurocrine Biosciences, INC. | $97.24 | 2023-2025 | Ingrezza, Ongentys |
| Merck Sharp & Dohme LLC | $95.53 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $67.24 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.51 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $51.09 | 2024-2025 | Trelegy Ellipta, Arexvy, Bexsero |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $42.84 | 2023-2025 | Aptiom, Gemtesa |
| Amgen INC. | $41.87 | 2022-2025 | Evenity |
| Novartis Pharmaceuticals Corporation | $38.09 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.86 | 2023-2025 | Xifaxan |
| Acceleron Pharma, INC. | $21.75 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $21.74 | 2024 | Austedo Xr |
| Eisai INC. | $21.72 | 2022 | |
| Exelixis INC. | $20.37 | 2022 | |
| Genmab U.S., INC. | $18.57 | 2022 | |
| Genzyme Corporation | $16.66 | 2022 | |
| Pharmacosmos Therapeutics INC. | $16.55 | 2022 | |
| Astellas Pharma US INC | $16.12 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.18 | 2023 | |
| Morphosys, US INC. | $14.90 | 2022 | |
| Vanda Pharmaceuticals INC. | $14.12 | 2025 | Fanapt |
| Medtronic, INC. | $14.01 | 2023 | Intellis Adaptivestim |
| Gilead Sciences, INC. | $13.18 | 2022 | |
| Celgene Corporation | $12.92 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.14 | 2022 | |
| Phathom Pharmaceuticals, INC. | $9.19 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Frame listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.